Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension

Liver Transplantation

Volumn 18, Issue 6, 2012, Pages 686-695

  Hollatz, Trina J ^a   Musat, Alexandru ^b   Westphal, Susanne ^a   Decker, Catherine ^a   D'Alessandro, Anthony M ^c   Keevil, Jon ^d   Zhanhai, Li ^a   Runo, James R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Division of Gastroenterology and Hepatology   (United States)

^c Division of Transplant Surgery   (United States)

^d Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; PROSTACYCLIN; SILDENAFIL; UNIPROST;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MORTALITY; PORTOPULMONARY HYPERTENSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEIZURE; TREATMENT WITHDRAWAL;

ADULT; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PORTAL; LENGTH OF STAY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; POSTOPERATIVE COMPLICATIONS; PULMONARY CIRCULATION; PURINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONES;

EID: 84861804487     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23407     Document Type: Article

References (22)

1. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB,; for ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24: 861-880.
2. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH,. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44: 1502-1510.
3. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI,. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107-1111.
4. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401-409.
5. Stauber RE, Olschewski H,. Portopulmonary hypertension: short review. Eur J Gastroenterol Hepatol 2010; 22: 385-390.
6. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP,. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-528.
7. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA,. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450.
8. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174-182.
9. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O,. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
10. Golbin JM, Krowka MJ,. Portopulmonary hypertension. Clin Chest Med 2007; 28: 203-218.
11. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151 (pt 1): 384-389.
12. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH,. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648.
13. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O'Mahony C, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 2006; 6: 2177-2182.
14. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ,. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445-2453.
15. Sakai T, Planinsic RM, Mathier MA, de Vera ME, Venkataramanan R,. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Transpl Int 2009; 22: 554-561.
16. Cadden IS, Greanya ED, Erb SR, Scudamore CH, Yoshida EM,. The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation. Ann Hepatol 2009; 8: 158-161.
17. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: 563-567.
18. Hemnes AR, Robbins IM,. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009; 15: 15-19.
19. Gough MS, White RJ,. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl 2009; 15: 30-36.
20. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD,. Portopulmonary hypertension: a report from the US-based REVEAL registry. Chest; doi:10.1378/chest.11-0160.
21. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637-643.
22. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007; 7: 1258-1264.